Debt-to-equity of Xilio Therapeutics, Inc. from 30 Jun 2022 to 30 Sep 2025

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Xilio Therapeutics, Inc. quarterly Debt-to-equity in % history and change rate from 30 Jun 2022 to 30 Sep 2025.
Xilio Therapeutics, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 1522%, a 832% increase year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Change (%)

Xilio Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period	Value	YoY Chg	Change %	Date
Q3 2025	1522%	+1358%	+832%	30 Sep 2025
Q2 2025	580%	+471%	+429%	30 Jun 2025
Q1 2025	310%	+238%	+331%	31 Mar 2025
Q4 2024	226%	+184%	+439%	31 Dec 2024
Q3 2024	163%	+128%	+358%	30 Sep 2024
Q2 2024	110%	+79%	+262%	30 Jun 2024
Q1 2024	72%	+45%	+165%	31 Mar 2024
Q4 2023	42%	+18%	+76%	31 Dec 2023
Q3 2023	36%	+15%	+73%	30 Sep 2023
Q2 2023	30%	-6.2%	-17%	30 Jun 2023
Q1 2023	27%			31 Mar 2023
Q4 2022	24%			31 Dec 2022
Q3 2022	21%			30 Sep 2022
Q2 2022	36%			30 Jun 2022

* An asterisk sign (*) next to the value indicates that the value is likely invalid.